Gómez-Ruiz M - Search Results

1

Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets.

Gómez-Ruiz M, Rodríguez-Cueto C, Luna-Piñel E, Hernández-Gálvez M, Fernández-Ruiz J. Gómez-Ruiz M, et al. Front Mol Neurosci. 2019 Apr 24;12:94. doi: 10.3389/fnmol.2019.00094. eCollection 2019. Front Mol Neurosci. 2019. PMID: 31068788 Free PMC article. Review.

2

Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias.

Rodríguez-Cueto C, Benito C, Romero J, Hernández-Gálvez M, Gómez-Ruiz M, Fernández-Ruiz J. Rodríguez-Cueto C, et al. Pathobiology. 2014;81(3):149-59. doi: 10.1159/000358127. Epub 2014 Mar 14. Pathobiology. 2014. PMID: 24642775 Free article.

3

Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3.

Rodríguez-Cueto C, Hernández-Gálvez M, Hillard CJ, Maciel P, García-García L, Valdeolivas S, Pozo MA, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. Rodríguez-Cueto C, et al. Neuroscience. 2016 Dec 17;339:191-209. doi: 10.1016/j.neuroscience.2016.09.046. Epub 2016 Oct 4. Neuroscience. 2016. PMID: 27717809

4

Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.

Rodríguez-Cueto C, Hernández-Gálvez M, Hillard CJ, Maciel P, Valdeolivas S, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. Rodríguez-Cueto C, et al. PLoS One. 2017 Apr 27;12(4):e0176521. doi: 10.1371/journal.pone.0176521. eCollection 2017. PLoS One. 2017. PMID: 28448548 Free PMC article.

5

Therapeutic potential of the endocannabinoid system in the brain.

Ramos JA, González S, Sagredo O, Gómez-Ruiz M, Fernández-Ruiz J. Ramos JA, et al. Mini Rev Med Chem. 2005 Jul;5(7):609-17. doi: 10.2174/1389557054368817. Mini Rev Med Chem. 2005. PMID: 16026307 Review.

6

The endocannabinoid system as a target for the treatment of neuronal damage.

Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E. Fernández-Ruiz J, et al. Expert Opin Ther Targets. 2010 Apr;14(4):387-404. doi: 10.1517/14728221003709792. Expert Opin Ther Targets. 2010. PMID: 20230193 Review.

7

Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.

Rodríguez-Cueto C, Benito C, Fernández-Ruiz J, Romero J, Hernández-Gálvez M, Gómez-Ruiz M. Rodríguez-Cueto C, et al. Br J Pharmacol. 2014 Mar;171(6):1472-89. doi: 10.1111/bph.12283. Br J Pharmacol. 2014. PMID: 23808969 Free PMC article.

8

Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies.

Fernández-Ruiz J, Gómez-Ruiz M, García C, Hernández M, Ramos JA. Fernández-Ruiz J, et al. Methods Enzymol. 2017;593:175-198. doi: 10.1016/bs.mie.2017.06.021. Epub 2017 Jul 4. Methods Enzymol. 2017. PMID: 28750802 Review.

9

Cannabinoids, multiple sclerosis and neuroprotection.

de Lago E, Gómez-Ruiz M, Moreno-Martet M, Fernández-Ruiz J. de Lago E, et al. Expert Rev Clin Pharmacol. 2009 Nov;2(6):645-60. doi: 10.1586/ecp.09.42. Expert Rev Clin Pharmacol. 2009. PMID: 22112258

10

Description of a bivalent cannabinoid ligand with hypophagic properties.

Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, Gómez-Ruíz M, Callado LF, Goya P, Rodríguez de Fonseca F, Martín MI, Fernández-Ruíz J, Meana JJ, Jagerovic N. Fernández-Fernández C, et al. Arch Pharm (Weinheim). 2013 Mar;346(3):171-9. doi: 10.1002/ardp.201200392. Epub 2013 Feb 1. Arch Pharm (Weinheim). 2013. PMID: 23371794

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

108 results

Search Page